Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics, a clinical-stage biopharmaceutical company focused on TGF-ß–related disorders, reported Q2 2026 with no revenue versus $18.2 million a year earlier, and first-half 2026 revenue of $0.4 million versus $229.4 million, reflecting the absence of prior-year Takeda license and service revenue.
Research and development expense fell to $22.3 million in Q2 2026 from $43.5 million as elritercept costs transitioned to Takeda and cibotercept spending declined; general and administrative expense decreased to $8.6 million. The company reported a Q2 net loss of $28.7 million and a first-half net loss of $52.4 million, compared with $117.8 million of net income in the prior-year period.
Cash and cash equivalents were $257.6 million as of June 30 2026, with total liabilities of $25.3 million, and management believes this will fund operations for at least 12 months. Elritercept is licensed globally (ex‑China) to Takeda, with potential milestones exceeding $1.1 billion; a $20 million development milestone was achieved in July 2026, of which 25% of net cash proceeds is expected to be distributed to stockholders. Lead asset rinvatercept is in a Phase 2 DMD trial with initial data expected in the first half of 2027, and regulatory engagement for an ALS Phase 2 study planned for the second half of 2026.
Keros Therapeutics, Inc. reported that it has issued a press release with its financial results for the quarter ended June 30, 2026. The press release, dated August 3, 2026, is provided as Exhibit 99.1 and is incorporated by reference for those detailed figures and disclosures.
Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under their license agreement for elritercept, triggered by dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial.
Under the global license, effective January 16, 2025, Keros previously received a $200 million upfront cash payment, is eligible for additional development, commercial and sales milestones that could exceed $1.1 billion, and may earn tiered royalties on net sales. Keros expects to distribute 25% of the net cash proceeds from this milestone payment to stockholders after receipt.
BlackRock, Inc. reports beneficial ownership of common stock of Keros Therapeutics, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 1,671,343 shares of Keros common stock, representing 8.4% of the class.
BlackRock has sole voting power over 1,645,352 shares and sole dispositive power over 1,671,343 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Keros’s outstanding common shares.
Keros Therapeutics, Inc. disclosed that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities. The Board appointed Corporate Controller and Vice President, Finance, Annita Tanini, age 55, as interim principal financial officer and principal accounting officer effective August 4, 2026, while a search for a new CFO is underway.
Under a new executive employment agreement, Ms. Tanini will receive an annual base salary of $302,300 and be eligible for an annual cash bonus targeted at 30% of base salary. If terminated without cause or she resigns for good reason, she may receive six months of base salary and up to six months of COBRA premium payments, subject to a release. Mr. Regnante will receive accrued salary and standard benefits under his existing employment agreement and is not entitled to additional severance beyond amounts required by law.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, increasing his direct holdings to 18,592 shares.
BlackRock Portfolio Management LLC reports beneficial ownership of common stock of Keros Therapeutics, Inc. on a Schedule 13G. The firm reports beneficial ownership of 1,122,874 shares of Keros common stock, representing 5.7% of the outstanding class.
BlackRock Portfolio Management LLC, organized in Delaware and based at 50 Hudson Yards, New York, reports sole voting power over 991,089 shares and sole dispositive power over 1,122,874 shares, with no shared voting or dispositive power. Various underlying persons may receive dividends or sale proceeds from these shares, but no single person is reported to hold more than five percent of Keros’ outstanding common stock.
Keros Therapeutics director Anne Prener received new equity awards. On July 1, 2026, she was granted 13,786 shares of Common Stock as restricted stock units (RSUs), with no cash paid per share. These RSUs vest over three years in twelve equal quarterly installments starting August 15, 2026, if she remains in continuous service.
On the same date, she was also granted a stock option for 14,870 shares of Common Stock at an exercise price of $10.88 per share, expiring on June 30, 2036. This option vests in equal quarterly installments over three years beginning October 1, 2026, also conditioned on continued service. The filing shows no open-market buying or selling; these are compensation-related grants.
Keros Therapeutics, Inc. filed an insider ownership report on Form 3 for Anne Prener
Keros Therapeutics has appointed Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026, as a Class III director with a term running through the 2029 annual stockholder meeting. She has no related-party ties to the company and joins as an independent non-employee director.
Dr. Prener will receive an initial stock option award with a grant date fair value of $150,000, capped at 0.075% of common shares outstanding, vesting quarterly over three years, plus an initial RSU award with the same value and cap vesting in 12 quarterly installments. Both awards fully vest upon a Change in Control.
On an ongoing basis, she will be eligible for annual option and RSU awards of $75,000 each, each capped at 0.0375% of shares outstanding, and will receive a $41,500 annual cash retainer. Keros also highlighted her extensive prior leadership roles at multiple biopharmaceutical companies and academic and advisory positions.